Form 4: Director Trades at Emergent BioSolutions

Donald W. DeGolyer, a Director at Emergent BioSolutions Inc., reported transactions involving the acquisition of restricted stock units and stock options, alongside the sale of common stock.

Summary

• Director Donald W. DeGolyer acquired 25,344 restricted stock units (RSUs) on April 30, 2026, as an annual grant for board and committee service. These RSUs are set to vest one year from the grant date, provided he remains on the board.
• On the same date, DeGolyer was granted 11,296 stock options, also for board and committee service, with a vesting date one year from the grant date and an exercise price of $7.99.
• On May 1, 2026, DeGolyer sold a total of 15,481 shares of common stock. These sales were conducted under a Rule 10b5-1 trading plan established on August 11, 2025, to cover tax obligations related to the vesting of RSUs on April 29, 2026.
• The sales occurred at weighted average prices: 14,527 shares at prices ranging from $7.78 to $8.64, and 954 shares at prices ranging from $8.80 to $8.99.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While it involves insider transactions, the acquisition of equity awards and the sale of shares under a pre-arranged 10b5-1 plan for tax purposes are routine and do not inherently signal positive or negative sentiment about the company's future prospects.

Positives

• Director received an annual grant of 25,344 restricted stock units, indicating continued equity-based compensation for service.
• Director was granted 11,296 stock options, providing potential future upside participation in the company's stock performance.
• Sales of stock were executed under a pre-established Rule 10b5-1 trading plan, suggesting a structured and pre-determined approach to managing equity holdings and tax liabilities.

Negatives

• Director sold a significant number of shares (15,481) shortly after the acquisition of RSUs and options.
• The sales were primarily to satisfy tax obligations, which could imply that the director needed to liquidate shares to cover these costs.

Risks

• The sale of shares by a director, even under a 10b5-1 plan, can sometimes be interpreted negatively by the market, potentially impacting investor sentiment.
• The company's stock performance is subject to various factors, which could affect the value of the director's unvested RSUs and stock options.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by a director at Emergent BioSolutions is a common practice for managing equity holdings and tax liabilities in a compliant manner, especially for executives and directors who may have access to material non-public information at other times.

Stakeholder Impact

• Shareholders: The sale of shares by a director, even under a 10b5-1 plan, may lead to minor short-term market fluctuations or perceptions, though the plan's existence mitigates concerns about opportunistic selling.
• Employees: No direct impact mentioned.
• Creditors: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Customers: No direct impact mentioned.

Next Steps

• The RSUs granted will vest on the day prior to the one-year anniversary of the grant date, subject to the reporting person remaining a member of the Company's board of directors.
• The stock options granted will vest on the Annual Grant Vesting Date, subject to the reporting person remaining a member of the Company's board of directors.

Key Dates

Keywords

Form 4, SEC Filing, Emergent BioSolutions, EBS, Director Transaction, Stock Options, Restricted Stock Units, Rule 10b5-1, Insider Trading, Equity Compensation